Proactive investors

Regenicin, Inc., is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs.

• 22/06/2011 Regenicin zahlt Lonza Walkersville Rechnung in voller Höhe
• 20/06/2011 Regenicin zahlt US$240.000 Darlehen zurück
• 10/06/2011 Regenicin: ehemaliger Firmenchef zieht Klage zurück

Regenicin, Inc., (OTC Bulletin Board: RGIN.OB) is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. Regenicin is currently working to bring the product candidate, PermaDerm™, to market.  PermaDerm™ is an exciting breakthrough technology that uses the patient’s own skin cells to generate living, tissue-engineered skin for the treatment of chronic burns and wounds. The company is publicly traded with headquarters in  New Jersey

Randall McCoy
Chairman and Chief Executive Officer

Randall McCoy has more than 37 years of experience in the healthcare industry. His experience includes executive positions and scientific research and development. His previous employment includes George Washington University, Temple University Medical School and RCA/SRI International (Director of Life Sciences and Electronic Displays). Mr. McCoy has assisted both small and major pharmaceutical/device companies address FDA issues. He has also helped over 225 foreign and domestic companies introduce their FDA regulated drug and medical device products into the US and World market. Mr. McCoy currently has over 30 Patents US and International.


Joe Connell M.S.
President

Joe Connell brings more than 26 years of pharmaceutical and biotechnology sales and marketing experience. His career started as a pharmaceutical sales representative with a major pharmaceutical company. He has had roles of increasing responsibility including COO, President and CEO of startup and specialty pharmaceutical companies, global responsibilities for nasal, pulmonary and aerosol drug delivery as well as formulations, analytical chemistry, stability and contract manufacturing of solids, liquids and parenterals. He has had the opportunity to hire, train and deploy the entire sales forces of several companies and his expertise in targeted selection, compensation, CRM automation and territory alignment. Joe has been instrumental in the launch of more than 25 major pharmaceutical products and devices. He has expertise in the areas of dermatology, wound healing, cardiovasculars, infectious diseases, gastroenterology, oncology, pain management, anesthesiology, and diabetes. Joe has been involved in global efforts with aerosol, nasal and pulmonary drug delivery devices.


John Weber
Interim CFO

John Weber most recently served as Executive Vice President of Fujifilm Medical Systems USA, the highest ranked American corporate officer, from 2006 until his departure in 2009. His responsibilities included overseeing all corporate activity with the exception of R&D. During that time Fujifilm was ranked as the fastest growing medical imaging company, consistently ranking #1 or #2 in customer satisfaction. From 1998 through 2006 he served as Senior Vice President, Operations at Fujifilm USA where he spearheaded the transition of the company from a film distributor to a digital medical informatics company. From 1986 until 1998 he served as CFO where he helped to profitably manage Fujifilm's growth from an employee base of 75 to over 1,000. Prior to his distinguished career at Fujifilm Medical Systems USA, Mr. Weber served as the CFO for the confectionary and drinks division of Cadbury Schweppes Limited for three years and as Corporate Controller for an additional five years.


Chris Hadsall
Chief Operating Officer

Chris Hadsall is a 10-year veteran of the United States Marine Corps. He took a break from the profit world to start and run the VET Foundation. In his role as the Executive Director of the VET Foundation Chris designed, developed and implemented a holistic reintegration program teaching wounded, ill and injured veterans a life altering transition methodology. Chris was also responsible for the financial health of the organization and served as the chief fundraiser. Prior to starting the VET Foundation Chris worked as a Regional Manager for Professional Staffing ABTS. In that role Chris guided the day-to-day operations, business development, and customer relations for a major West Coast Expansion. He was promoted to that job after a successful stand up of a division inside Professional Staffing ABTS that focused on hiring returning Veterans from Iraq and Afghanistan. He also was responsible for managing community relations and outreach for the Company.


Richard Koeninger
Director of Regulatory Affairs

Richard Koeninger has 29 years as a Field Investigator, Drug and Device Specialist with The US Food and Drug Administration. His duties overseas included Associate Director for the Division of Emergency and Investigational Operations, Criminal Investigator, Compliance Officer and Resident in Charge. Mr. Koeninger has served on clinical trials Institutional Review Boards (IRB) and has conducted FDA pre-approval medical device and pharmaceutical investigations. While at the FDA, Mr. Koeninger held the distinction of being the International FDA Expert for Drugs and Devices.


Lauri-Ann Hahn R.N., B.S.N.
Director of Clinical Trials

Lauri Hahn has been involved with clinical trials/research since 1998. She has developed and trained Good Clinical Practices quality systems. Lauri is experienced in all areas of Clinical Research from planning and conducting studies to Clinical Report submissions to the FDA. Lauri served as Associate Director of Clinical Trials/Senior Project Manager for Lonza Walkersville, Inc. (an affiliate of Lonza Group Ltd.) from 2006 to 2008 wherein she gained direct experience working with the Cultured Skin Substitute. Prior to working at Lonza, Lauri work at the National Institutes of Health (NIH). From 2001 to 2005, Ms. Hahn was the Head of Clinical Research at the University of Pittsburgh Department of Urology. Lauri has held positions as a Sponsor, a member of a Clinical Research Organization and Clinical Sub-Investigator. She graduated from the University of Pittsburgh in 1993 with a Bachelors of Science Degree in Nursing.

No info available.

• Inovio Pharmaceuticals (NYSE AMEX: ino)
• NanoViricides (OTCBB: NNVC)
• OTCBB (OTCBB: POSC)
• Positron Corporation (OTCBB: POSC)
• Silence Therapeutics (AIM: SLN)
• smartFOCUS Group (AIM: STF)
• Wound Management Technologies, Inc (OTCQB: WNDM)